This page shows the latest Ultibro Breezhaler news and features for those working in and with pharma, biotech and healthcare.
Novartis and Propeller will connect the Breezhaler devices to Propeller's digital platform via a new custom sensor will passively record and transmit treatment compliance data. ... The inhaler is currently used as part of Novartis' Ultibro Breezhaler,
Vectura recorded revenues of £26m in the six-month period ended September 2015 - up 35% - as royalties increased on products such as Novartis' Ultibro Breezhaler (indacaterol/glycopyrronium bromide).
The next-generation Breezhaler falls within the pharma firm's collaboration with Qualcomm, whose Qualcomm Life subsidiary provides wireless solutions for the management of chronic diseases and sharing of medical information. ... Novartis plans a 2019
Becomes first dual action bronchodilator approved in EU for COPD. Novartis' Ultibro Breezhaler has become the first dual action bronchodilator to be approved in the EU for chronic obstructive pulmonary disease ... Many COPD patients will now have a
Novartis COPD inhaler recommended in EU. Elsewhere among the CHMP's recommendations, Novartis received backing for the Ultibro Breezhaler as a once-daily maintenance treatment to relive symptoms in adults with ... The product, which is to be marketed as
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...